Squamous-state excursions activate APOBEC3A in cancer
Josefine Striepen1, Alexandra Dananberg1, Aušrinė Ruzgaitė1
1Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Abstract:
The cytidine deaminase APOBEC3A is a major endogenous mutagen in human cancer, yet is rarely captured in bulk tumor RNA or protein profiles despite the prominent mutational scars it leaves in cancer genomes. The origin of these episodic mutational bursts has remained unclear, with prevailing models emphasizing sustained inflammatory signaling. Here, we show that APOBEC3A is induced in a rare subpopulation of cancer cells engaging a transient squamous differentiation program, linking APOBEC3A mutagenesis to lineage-state plasticity rather than persistent inflammatory signaling. Across breast and lung cancer cell lines and patient tumors, keratinocyte differentiation markers, including the stress keratins KRT6A and KRT16, are the strongest correlates of endogenous APOBEC3A expression. These days-long squamous-state excursions explain how APOBEC3A can leave durable mutational scars while remaining largely invisible to bulk tumor RNA and protein profiling. APOBEC3A catalytic activity reinforces selected components of this program through uracil excision and JNK-AP-1 signaling. The squamous differentiation transcription factor ZNF750 promotes APOBEC3A induction during squamous-state engagement in breast and lung cancer models. In established human squamous tumors, however, ZNF750 loss-of-function is associated with elevated APOBEC3A expression and APOBEC mutagenesis, revealing lineage-context-dependent regulation. These findings identify a transient differentiation state as a mutagenic intermediate, coupling cell-state plasticity to cancer genome evolution.
Insights
Cytidine deaminase APOBEC3A drives cancer mutations during transient squamous differentiation, not inflammation. This cell plasticity links to cancer genome evolution, explaining APOBEC3A
Area of Science:
- Cancer Biology
- Genetics
- Cellular Differentiation
Background:
- APOBEC3A (cytidine deaminase) is a significant endogenous mutagen in human cancer.
- Its mutational signatures are evident in cancer genomes, but expression is often missed in bulk analyses.
- The source of APOBEC3A's episodic mutagenic activity has been attributed to inflammatory signaling.
Purpose of the Study:
- To investigate the cellular origin and regulation of APOBEC3A-driven mutagenesis in cancer.
- To link APOBEC3A activity to specific cellular states and signaling pathways.
- To understand the role of lineage-state plasticity in cancer genome evolution.
Main Methods:
- Analysis of APOBEC3A expression in breast and lung cancer cell lines and patient tumors.
- Correlation of APOBEC3A levels with keratinocyte differentiation markers (KRT6A, KRT16).
- Investigation of APOBEC3A's catalytic activity effects on signaling pathways (JNK-AP-1).
- Role of transcription factor ZNF750 in APOBEC3A regulation during differentiation.
Main Results:
- APOBEC3A is induced in a rare subpopulation of cancer cells undergoing transient squamous differentiation.
- Squamous differentiation markers strongly correlate with APOBEC3A expression, explaining its transient nature.
- APOBEC3A activity reinforces squamous differentiation via uracil excision and JNK-AP-1 signaling.
- ZNF750 promotes APOBEC3A induction in models, but its loss elevates APOBEC3A in human squamous tumors.
Conclusions:
- Transient squamous differentiation, a form of cell-state plasticity, is a key driver of APOBEC3A mutagenesis.
- This mechanism explains how APOBEC3A leaves mutational scars while evading bulk detection.
- Lineage-context-dependent regulation of APOBEC3A by ZNF750 influences cancer genome evolution.
Related Concept Videos
Cancer Cell Migration through Invadopodia
The Intrinsic Apoptotic Pathway
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Induced Pluripotent Stem Cells
Somatic cells are...
Apoptosis


